Pharma Strategy Blog

Commentary on Pharma & Biotech Oncology / Hematology New Product Development

Posts tagged ‘aberrations’

Cancer Clinical Trials: Companion Diagnostics or Gene Sequencing?

Last year saw some interesting developments from MD Anderson Cancer Center in early phase clinical trials that may have a far-reaching impact on the future of cancer research as we know it:

  1. At ASCO in June, Dr Tsimberidou presented the initial results from a phase I study run by the MD Anderson Department of Investigational Cancer Therapeutics group. Instead of testing patients with a given cancer (eg lung) for individual mutations eg ALK or EGFR and then offering patients a targted drug as we normally do, they ran a broad diagnostic panel across a multitude of patients with different cancers to determine what the tumour was telling them about the aberrations and selected appropriate targeted therapies. While the study was small in size, the results were better than random selection.
9 Comments

Is the cancer research paradigm changing?

Over the weekend, a reader (a scientist in translational medicine) kindly sent me the link to a paper on PARP inhibition and asked:

"Is this a sign of the new wave of oncology drug development? Rather than basing treatment on cancer tissue type (eg. breast, prostate, colorectal), the underlying genetic mutation regardless of tissue of origin will be used for targeted agents. Imagine a randomized Ph2 trial of all BRCA1/2 deficient patients vs. non-mutated patients. Of course, this same rationale would have not worked for K-ras mutation patients with EGFR inhibitors in NSLCLC vs. Colorectal."

My short answer is basically, yes.

3 Comments